drugset / Trial / NCT02612779

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

NCT02612779

Phase 2 Completed 74 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.

Timeline

Start
2016-02-09
Primary completion
2019-07-29
Completion
2020-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule
Subject Elotuzumab Monoclonal antibody
Subject Nivolumab Monoclonal antibody
Subject Pomalidomide Other / unclassified

Indications